Drug shows promise in halting rare body overgrowth disorder

NCT ID NCT02443818

Completed Disease control Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated May 15, 2026 · Updated 21 times

Summary

This study tested a drug called sirolimus in 16 people with a rare condition causing parts of their body to grow too much due to a PIK3CA gene change. The goal was to see if sirolimus could stop or slow this overgrowth. Participants took the drug and were monitored with scans and measurements to track changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

CHRU de Montpellier - Hôpital Saint-Eloi

Montpellier, 34295, France
CHRU de Tours

Tours, 37044, France
CHU Paris - Necker

Paris, 75015, France
CHU d'Angers

Angers, 49933, France
CHU de Bordeaux - GH Pellegrin

Bordeaux, 33076, France
CHU de DIJON

Dijon, 21079, France
HCL Lyon - CH Lyon Sud

Pierre-Bénite, 69495, France
Hopitaux de Brabois Chu Nancy

Nancy, 54511, France
Hôpital Jeanne de Flandre

Lille, 59037, France
Hôpital mère-enfant de Nantes

Nantes, 44093, France
Pôle Cardiovasculaire et Métabolique - Hôpital Larrey

Toulouse, 31059, France

Conditions

Explore the condition pages connected to this study.

SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA